Modality
Degrader
MOA
KRASG12Di
Target
Nectin-4
Pathway
Amyloid
HNSCCADHD
Development Pipeline
Preclinical
~Feb 2018
→ ~May 2019
Phase 1
~Aug 2019
→ ~Nov 2020
Phase 2
Feb 2021
→ Jun 2025
Phase 2Current
NCT03524700
1,911 pts·ADHD
2021-02→2025-06·Completed
1,911 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-06-0110mo agoPh2 Data· ADHD
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P2
Complet…
Catalysts
Ph2 Data
2025-06-01 · 10mo ago
ADHD
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03524700 | Phase 2 | ADHD | Completed | 1911 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| ION-3857 | Ionis | Preclinical | Nectin-4 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα |